Eiko Lifesciences Ltd

For the fourth consecutive session, Eiko Lifesciences Ltd has closed lower, culminating in a fresh 52-week low of Rs 43 on 15 Sep 2026. This marks a 33.3% decline from its 52-week high of Rs 64.44, underscoring sustained selling pressure despite some positive financial signals.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

A sharp decline over the past two sessions has dragged Eiko Lifesciences Ltd to a fresh 52-week low of Rs 44.75 on 17 Aug 2026, marking a 7.04% intraday drop and extending its losing streak to five sessions. This downturn contrasts with the broader market, where the Sensex remains above its 50-day moving average despite a modest fall of 0.57% on the day.

Eiko Lifesciences Ltd, a micro-cap player in the Specialty Chemicals sector, reported a notably positive quarterly performance for June 2026, with robust revenue growth and record profitability metrics. Despite a downgrade in its Mojo Grade from Hold to Sell, the company’s latest financials reveal encouraging signs of operational strength, though challenges remain in its broader market performance and valuation.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 August 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 July 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and technical outlook.

Eiko Lifesciences Ltd., a speciality chemicals manufacturer, reported a consolidated net profit of ₹1.30 crores for Q4 FY26, marking a modest sequential increase of 7.44% from ₹1.21 crores in Q3 FY26, though significantly ahead of the ₹1.05 crores posted in Q4 FY25—a year-on-year gain of 23.81%. The micro-cap company, with a market capitalisation of ₹73.00 crores, saw its stock surge 7.39% on May 26 to close at ₹53.03, as investors responded positively to the topline momentum despite lingering concerns about profitability metrics and weak return ratios.

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.